中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
14期
2159-2161
,共3页
心肌缺血%C反应蛋白%半胱氨酸%普罗布考
心肌缺血%C反應蛋白%半胱氨痠%普囉佈攷
심기결혈%C반응단백%반광안산%보라포고
Myocardial ischemia%C-reactive protein%Cysteine%Probucol
目的 探讨普罗布考对非ST段抬高型急性冠脉综合征患者血浆超敏C反应蛋白(hs-CRP)和同型半胱氨酸(Hcy)的影响.方法 82例非ST段抬高型急性冠脉综合征患者随机数字表法分为观察组42例,对照组40例.对照组采用常规治疗,观察组在常规治疗的基础上加用普罗布考,两组均治疗3个月.比较治疗前后两组患者血浆hs-CRP和Hcy水平.结果 两组治疗后血浆hs-CRP和Hcy均较治疗前明显降低,并且观察组降低hs-CRP[(0.82±0.43) mg/L与(1.05±0.52) mg/L,t=2.1871,P＜0.05]和Hcy[(10.08±7.18) μmol/L与(15.73±9.16) μmol/L,t=3.1168,P＜0.05]更明显.结论 普罗布考可以通过降低hs-CRP和Hcy而稳定非ST段抬高型急性冠脉综合征患者的斑块.
目的 探討普囉佈攷對非ST段抬高型急性冠脈綜閤徵患者血漿超敏C反應蛋白(hs-CRP)和同型半胱氨痠(Hcy)的影響.方法 82例非ST段抬高型急性冠脈綜閤徵患者隨機數字錶法分為觀察組42例,對照組40例.對照組採用常規治療,觀察組在常規治療的基礎上加用普囉佈攷,兩組均治療3箇月.比較治療前後兩組患者血漿hs-CRP和Hcy水平.結果 兩組治療後血漿hs-CRP和Hcy均較治療前明顯降低,併且觀察組降低hs-CRP[(0.82±0.43) mg/L與(1.05±0.52) mg/L,t=2.1871,P＜0.05]和Hcy[(10.08±7.18) μmol/L與(15.73±9.16) μmol/L,t=3.1168,P＜0.05]更明顯.結論 普囉佈攷可以通過降低hs-CRP和Hcy而穩定非ST段抬高型急性冠脈綜閤徵患者的斑塊.
목적 탐토보라포고대비ST단태고형급성관맥종합정환자혈장초민C반응단백(hs-CRP)화동형반광안산(Hcy)적영향.방법 82례비ST단태고형급성관맥종합정환자수궤수자표법분위관찰조42례,대조조40례.대조조채용상규치료,관찰조재상규치료적기출상가용보라포고,량조균치료3개월.비교치료전후량조환자혈장hs-CRP화Hcy수평.결과 량조치료후혈장hs-CRP화Hcy균교치료전명현강저,병차관찰조강저hs-CRP[(0.82±0.43) mg/L여(1.05±0.52) mg/L,t=2.1871,P＜0.05]화Hcy[(10.08±7.18) μmol/L여(15.73±9.16) μmol/L,t=3.1168,P＜0.05]경명현.결론 보라포고가이통과강저hs-CRP화Hcy이은정비ST단태고형급성관맥종합정환자적반괴.
Objective To explore the influence of probucol on high-sensitive C-reactive protein (hs-CRP)and homocysteine(Hcy) of patients with non-ST-segment elevation acute coronary syndrome.Methods 82 patients with non-ST-segment elevation acute coronary syndrome were randomly divided into two groups,the control group (40 cases) and the treatment group (42 cases).The patients in the control group were treated through the conventional treatment,while the patients in the treatment group were treated by probucol on the basis of conventional therapy.They were all treated for three months.Serum levels of hs-CRP and Hcy were detected before and after treatment.Results Serum levels of hs-CRP and Hcy were all decreased after treatment in both two groups.The hs-CRP and Hcy in the treatment group were significantly improved than those of the control group [(0.82 ± 0.43) mg/L vs (1.05 ± 0.52) mg/L,(10.08 ± 7.18) μnol/L vs (15.73 ± 9.16) μmol/L,t =2.1871,3.1168,all P ＜ 0.05].Conclusion Probucol can significantly decrease the serum levels of hs-CRP and Hcy in patients with non-ST-segment elevation acute coronary syndrome.
